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Antigen stimulation of immune cells activates
the transcription factor NFAT, a key regulator
of T cell activation and anergy. NFAT forms co-
operative complexes with the AP-1 family of
transcription factors and regulates T cell activa-
tion-associated genes. Here we show that reg-
ulatory T cell (Treg) function is mediated by an
analogous cooperative complex of NFAT with
the forkhead transcription factor FOXP3, a line-
age specification factor for Tregs. The crystal
structure of an NFAT:FOXP2:DNA complex re-
veals an extensive protein-protein interaction
interface between NFAT and FOXP2. Struc-
ture-guided mutations of FOXP3, predicted to
progressively disrupt its interaction with NFAT,
interfere in a graded manner with the ability of
FOXP3 to repress expression of the cytokine
IL2, upregulate expression of the Treg markers
CTLA4 and CD25, and confer suppressor func-
tion in a murine model of autoimmune diabetes.
Thus by switching transcriptional partners,
NFAT converts the acute T cell activation pro-
gram into the suppressor program of Tregs.
INTRODUCTION
Eukaryotic genes are regulated through the coordinated
actions of multiple transcription factors, which typically
engage in combinatorial interactions on DNA (Levine and
Tjian, 2003; Miner and Yamamoto, 1991). A well-knownexample of combinatorial transcriptional control is pro-
vided by NFAT, four calcium-regulated transcription fac-
tors (NFAT1–4) that regulate gene expression in diverse
organs including the immune system, muscle, bone, and
brain (Crabtree and Olson, 2002; Hogan et al., 2003).
NFAT is critical for the differentiation of many cell types in-
cluding osteoclasts, slow twitch muscle fibers, and effec-
tor T cells (Crabtree and Olson, 2002; Hogan et al., 2003).
In cardiac, skeletal, and smooth muscle cells, the relevant
interactions are between NFAT and GATA proteins (Hogan
et al., 2003), whereas in activated T cells, NFAT forms
strong cooperative complexes with AP-1 (Fos-Jun) pro-
teins on composite NFAT:AP-1 DNA elements (Rao et al.,
1997). Under conditions of productive T cell activation,
NFAT:AP-1 complexes turn on expression of activation-
associated genes, whereas under conditions of partial
activation (i.e., Ca signaling alone), NFAT activates a dis-
tinct set of AP-1-independent genes, which encode nega-
tive regulators of T cell signaling and contribute to T cell
‘‘anergy’’ (Heissmeyer et al., 2004; Heissmeyer and Rao,
2004; Macian et al., 2002).
The FOXP family of transcription factors (FOXP1–4)
plays critical roles in development (Carlsson and Mahla-
puu, 2002). A mutation in the DNA binding domain of
FOXP2 cosegregates with a congenital speech disorder
(Lai et al., 2001), whereas mutations in FOXP3 are linked
to autoimmune disease (Ziegler, 2006). Male scurfy mice,
which are natural null mutants for the X-linked Foxp3 gene,
die 3–4 weeks after birth as a result of aggressive autoim-
munity with multiorgan infiltration (Brunkow et al., 2001).
Humans with mutations in FOXP3 develop a similar auto-
immune syndrome termed IPEX (immunodysregulation,
polyendocrinopathy, enteropathy, X-linked syndrome),
characterized by insulin-dependent diabetes, thyroiditis,Cell 126, 375–387, July 28, 2006 ª2006 Elsevier Inc. 375
massive T cell infiltration into the skin and gastrointestinal
tract, high levels of serum autoantibodies, and chronic
wasting (Bennett et al., 2001; Wildin et al., 2001). There is
compelling evidence that FOXP3 serves as a lineage spec-
ification factor for regulatory T cells, a class of T cells that
develops primarily in the thymus and is essential for main-
taining self-tolerance (Fontenot et al., 2003; Hori et al.,
2003; Khattri et al., 2003). T cells from Foxp3-transgenic
mice, and primary T cells transduced with Foxp3, acquire
many phenotypic and functional characteristics of thy-
mic-derived T regulatory cells (hereafter termed Tregs): in-
creased surface expression of the Treg surface markers
CD25, CTLA-4, CD103, and GITR; decreased production
of IL-2, IFN-g, and IL- 4 upon restimulation; and ability to
suppress effector CD4 T cells in cell culture and in mice
(Fontenot et al., 2003; Hori et al., 2003; Khattri et al.,
2001, 2003).
Notably, many of the genes regulated by FOXP3 are
also target genes for NFAT. The IL2 and IL4 genes are ac-
tivated by NFAT and repressed by FOXP3, while the CD25
and CTLA4 genes are upregulated by both NFAT and
FOXP3 (Hogan et al., 2003; Hori et al., 2003; Rao et al.,
1997). The mechanism by which FOXP3 influences the
expression of NFAT-dependent genes is unknown. Based
on the discovery of an IL2 promoter element that contains
a binding site for forkhead proteins adjacent to a binding
element for NFAT (Schubert et al., 2001; Wang et al.,
2003), it has been suggested that FOXP3 represses IL-2
expression by competing with NFAT for binding to DNA
(Schubert et al., 2001; Coffer and Burgering, 2004; Fonte-
not and Rudensky, 2005). An alternative possibility, based
on the finding that NFAT and FOXP3 physically interact in
cell lysates (Bettelli et al., 2005), is that FOXP3 represses
NFAT-driven cytokine transcription by sequestering
NFAT away from DNA. The most intriguing possibility,
however, is that both the repressive effect of FOXP3 on
cytokine gene expression and its activating effect on the
CTLA4 and CD25 Treg marker genes reflect cooperative
complex formation between NFAT and FOXP3. We pro-
vide evidence for this mechanism here.
RESULTS
FOXP3 Represses NFAT:AP-1-Dependent
Transcription and Forms a Cooperative Complex
with NFAT
Using reporter assays in Jurkat T cells, we showed that
the repressive activity of FOXP3 targets the cooperative
NFAT:AP-1 complex rather than other configurations of
NFAT (Figures 1 and S1). FOXP3 repressed reporter activ-
ity driven by three tandem copies of the murine Il2 pro-
moter ARRE2 element, a prototypical NFAT:AP-1-com-
posite site (Chen et al., 1998; Rao et al., 1997) but did
not inhibit the activity of a GAL4 fusion protein containing
only the transactivation domain (TAD) of NFAT1 (Luo et al.,
1996; Okamura et al., 2000) (Figures S1A and S1B). To ex-
clude the possibility that FOXP3 inhibited Ca2+/calcineurin
signaling upstream of NFAT, we coexpressed FOXP3 with376 Cell 126, 375–387, July 28, 2006 ª2006 Elsevier Inc.a constitutively active (CA) NFAT1 (Macian et al., 2002;
Okamura et al., 2000) and treated the cells with cyclo-
sporin A (CsA) to prevent activation of endogenous NFAT.
FOXP3 repressed the transcriptional activity of CA-NFAT1
at the ARRE2 NFAT:AP-1 element (Figure 1A) but not at
the Tnf promoter k3 element, a palindromic NFkB-like
site at which NFAT forms dimers (McCaffrey et al., 1994)
(Figure 1B). We conclude that FOXP3 targets nuclear
NFAT, acting specifically on NFAT:AP-1 complexes as
opposed to dimeric forms of NFAT.
The AP-1 binding sequence in the Il2 promoter ARRE2
site resembles consensus binding sites for forkhead pro-
teins (Carlsson and Mahlapuu, 2002) and for FOXP1
(Wang et al., 2003) (Figure 1C). The forkhead (FKH) do-
mains of three different FOXP proteins, FOXP1, FOXP2,
and FOXP3, bound very poorly to the ARRE2 composite
site in the absence of NFAT but formed clear cooperative
complexes when the NFAT1 DNA binding domain (Rel
homology region, RHR) was included in the binding reac-
tion (Figures 1C and S1). This behavior is reminiscent of
AP-1, which also binds poorly to this composite site in
the absence of NFAT but forms a strong cooperative com-
plex in its presence (Chen et al., 1998; Jain et al., 1993).
Thus FOXP3 represses NFAT:AP-1 activity, not by dis-
placing NFAT from NFAT:AP-1 composite sites as sug-
gested previously (Schubert et al., 2001), but rather by
forming a cooperative NFAT:FOXP3:DNA complex that re-
sembles the cooperative NFAT:Fos:Jun:DNA complex.
Crystal Structure of a Ternary NFAT:FOXP2:DNA
Complex
To analyze the details of the NFAT:FOXP interaction, we
crystallized a ternary complex of the NFAT1 RHR and
the FOXP2 forkhead domain bound to double-stranded
DNA containing the murine Il2 promoter ARRE2 site. The
crystal structure was solved by molecular replacement
at 2.7 A˚ (Table S1). Two NFAT1:FOXP2:DNA complexes
with a similar overall structure are observed in the asym-
metric unit (Figure 2A); in each complex, the RHR of NFAT
binds to the 50 half of the ARRE2 site, while the FOXP2
forkhead domain adopts a typical winged-helix fold and
binds to the 30 half of the ARRE2 site. The two proteins
form an extended interaction interface on ARRE2 DNA,
burying 614 A˚2 of solvent-accessible surface (Figure 2B).
The detailed DNA binding interactions are similar to
those seen in previously characterized NFAT:DNA and
FOXP2:DNA complexes (Chen et al., 1998; Giffin et al.,
2003; Jin et al., 2003; Stroud and Chen, 2003; Stroud
et al., 2006) (Figures 2C and 2D). Unexpectedly, however,
FOXP2 binds different regions of the murine ARRE2 site in
the binary FOXP2:DNA and ternary NFAT:FOXP2:DNA
complexes (Figure 2E). In the binary complex (Stroud
et al., 2006), FOXP2 binds the sequence 50-GGAA
AATTTGTTTCA-30 (site A; FOXP binding sites are under-
lined, bases in bold match with the in vitro selected
sequence), which is a better match with the sequence se-
lected in vitro by Foxp1 (50-TATTT(G/A)T-30) (Wang et al.,
2003). In the NFAT1:FOXP2:DNA ternary complex, FOXP2
Figure 1. FOXP3 Specifically Represses NFAT:AP-1-Driven Transcription in Jurkat T Cells and Forms a Cooperative Complex with
NFAT on DNA
(A) Left, FOXP3 inhibits transcription driven by CA-NFAT1 on the ARRE2 NFAT:AP-1 sites. Right, Structure of the NFAT:AP-1:DNA complex. The
sequence of the murine ARRE2 composite element is shown below, with NFAT and AP-1 binding sites in green and red, respectively (Chen et al.,
1998). RHR-N, RHR-C: N- and C-terminal domains of the NFAT1 RHR.
(B) Left, FOXP3 does not inhibit the activity of CA-NFAT1 dimers on the k3 site from the Tnf promoter. Right, Structure of an NFAT dimer on a palin-
dromic NFkB-like site (Jin et al., 2003).
(C) Left, Cooperative binding of recombinant NFAT1 DNA binding domain and FOXP3 forkhead domain to Il2 ARRE2 DNA. Numbers give concen-
trations in mM. Right, Alignment of the consensus binding site for forkhead proteins (Carlsson and Mahlapuu, 2002) with the ARRE2 composite
site. NFAT and AP-1 sites are shown in green and underlined, respectively, and the overlap with the forkhead consensus site is shown in red.binds a different, presumably lower-affinity, site 50-GG
AAAATTTGTTTCA-30 (site B; FOXP binding sites are
underlined, bases in bold match with the in vitro selected
sequence). Notably, site B which is permissive for NFAT:
FOXP interaction is conserved in the human ARRE2 site
whereas site A which is nonpermissive is not (Figure 2E),
suggesting that the NFAT:FOXP interaction on the Il2 pro-
moter has been maintained in evolution for functional rea-
sons. The extensive protein-protein interactions between
NFAT and FOXP (see below) may compensate for poten-
tial lower-affinity binding of FOXP2 to the nonconsensus
site B, yielding a ternary NFAT:FOXP2:DNA complexthat is thermodynamically more stable than the binary
FOXP2:DNA complex.
Superposition of the NFAT1:FOXP2:DNA and NFAT1:
Fos:Jun:DNA complexes reveals that NFAT1 binds the
50 half of the ARRE2 element (GGAAA) almost identically
in both complexes, whereas FOXP2 occupies the same
DNA region as Fos:Jun (Figures 3A and S2A). In both com-
plexes, the ARRE2 DNA appears to undergo adaptive
structural changes to maximize protein-protein inter-
actions, bending upward by about 20 degrees in the
NFAT:Fos:Jun:DNA complex to allow the top part of the
Fos-Jun coiled-coil to interact with NFAT (Chen et al.,Cell 126, 375–387, July 28, 2006 ª2006 Elsevier Inc. 377
Figure 2. Overall Structure of the NFAT1:
FOXP2:DNA Complex
(A) Structure of the asymmetric unit showing
two complexes of NFAT1 (RHR-N: yellow;
RHR-C: green) and FOXP2 (red) bound to the
ARRE2 DNA (stick model).
(B) Surface representation of the NFAT1:
FOXP2:DNA ternary complex viewed from un-
derneath. The areas with relatively positive
surface potential (blue) from both proteins form
a combined DNA binding surface. The bend of
the ARRE2 DNA (stick model), following the
path of the combined DNA binding surface, is
apparent from this view.
(C) Detailed interactions between NFAT1 and
DNA.
(D) Detailed interactions between FOXP2 and
DNA in the ternary NFAT:FOXP2:DNA com-
plex. One notable difference from the FOXP2:
DNA binary complex (Stroud et al., 2006) is
that the highly conserved Arg553, which is mu-
tated in a severe speech disorder, interacts di-
rectly with Gua10 (bold) (50-TGTTT-3) through
hydrogen bonding in the ternary complex, in
contrast to a water-mediated hydrogen bond
between Arg553 and the adjacent thymidine
(bold) (50-TGTTT-30) in the binary complex.
Thus, Arg553 appears to play a more direct
role in DNA recognition in the ternary complex
than in the binary complex.
(E) Side view of the NFAT1:FOXP2:DNA com-
plex. FOXP2 (pink) bound to site A in the binary
FOXP2:mARRE2 complex (Stroud et al., 2006)
is modeled to show the lack of interaction
with NFAT. Site B (solid underline), which sup-
ports the NFAT:FOXP interaction, is conserved
between murine (top) and human (bottom)
ARRE2 elements, whereas site A (dashed un-
derline), which does not support the inter-
action, is not conserved.1998; Figure S2A) but bending to the side by about 20 de-
grees in the NFAT1:FOXP2:DNA complex, apparently to
align the NFAT and FOXP interfaces for optimal interaction
(Figure S2B). This sideways bend is seen in both com-
plexes of the asymmetric unit, suggesting that the bends
are not due to crystal packing but are induced by interac-
tions with the distinct partner proteins.
Although the two copies of NFAT1 in the asymmetric
unit show different orientations in the C-terminal domain
(RHR-C), the NFAT:FOXP interface is nearly identical in
the two NFAT1:FOXP2:DNA complexes (Figure S2C).
Helix H2 of FOXP2 packs against the E’F loop of NFAT1,
whereas Wing1 of FOXP2 inserts into a large groove
formed by the CX loop, the C-terminal stem of the E’F
loop, and the fg loop of NFAT1 (Figure 3B). Arg537 of
NFAT inserts deeply into the minor groove of DNA, sepa-
rating the NFAT and FOXP binding sites; this positive
charge and the AT-rich sequence in this region may ex-
plain the significantly compressed minor groove (Williams
and Maher, 2000), which apparently helps to bring the
interaction surfaces of NFAT and FOXP2 together (Fig-
ure 3C). Overall, the NFAT1:FOXP2 interface is primarily378 Cell 126, 375–387, July 28, 2006 ª2006 Elsevier Inc.polar and contains small hydrated pockets between major
foci of contact. These structural features are similar to
those of the NFAT:AP-1 interface (Chen et al., 1998)
and may explain why NFAT1 and FOXP2 (like NFAT and
AP-1) do not form stable complexes in the absence of
DNA (Figure S1F). The FOXP binding residues on NFAT1
are conserved in NFAT2–4 (Figure S3), suggesting a con-
served FOXP binding surface in the NFAT family. This
structure-based alignment also shows that NFAT uses
overlapping as well as distinct residues to bind Fos;Jun
and FOXP2, respectively.
Structure-Based Mutagenesis of NFAT-Interacting
Residues in FOXP3
We took advantage of the high sequence conservation
of the forkhead domains of FOXP proteins (Figure 3D) to
engineer various structure-guided mutations into the
predicted NFAT:FOXP3 interface. We focused on NFAT-
interacting residues oriented away from the DNA binding
surface of FOXP3, whose mutation was expected to
have a minimal effect on protein folding and stability.
(1) RR mutant (E399R E401R): E399 and E401 of FOXP3
Figure 3. Protein-Protein Interactions
between NFAT and FOXP
(A) Comparison of crystal structures of NFAT
with its partner proteins on the murine ARRE2
site. Fos-Jun and FOXP2 occupy essentially
the same region of DNA. The GGAA sequence
contacted by NFAT is shown in bold. Left, the
NFAT:Fos:Jun:DNA complex (Chen et al.,
1998). The AP-1 site is underlined. Right, The
NFAT:FOXP2:DNA complex. The FOXP site
embedded in the AP-1 site is highlighted in
bold. RHR-N, RHR-C: N- and C-terminal do-
mains of the NFAT1 RHR.
(B) Top view of the NFAT1:FOXP2:DNA ternary
complex in superimposed surface and ribbon
representations. NFAT and FOXP2 are colored
as in Figure 2A. DNA is in magenta. HNF-3
(FOXA3), which is superimposed on FOXP2, is
colored in blue. The structural elements of
NFAT and FOXP2 that participate in protein-
protein interactions are indicated (see text).
(C) Protein-protein interactions between NFAT1
and FOXP2. Residues at the binding interface
between NFAT1 (RHR-N: yellow; RHR-C:
green) and FOXP2 (pale red) on DNA (magenta)
are colored according to their proteins.
(D) Sequence alignment of FOXP1, FOXP2, and
FOXP3. Residues interacting with DNA are
shaded in magenta, residues interacting with
NFAT are shaded in green. Substitutions intro-
duced at NFAT-contacting residues of FOXP3
are indicated.are predicted to form salt bridges with the fg loop of
NFAT1 (K664R665K666R667) (Figures 3C and 3D). This loop
contains conserved positively charged residues in all
NFAT proteins (Figure S3). We engineered charge sub-
stitutions at these positions into FOXP3, thereby generat-
ing the RR mutant. (2) Wing1 insert mutant: Wing1 is
uniquely short in the FOXP family compared to other fork-
head proteins, and this feature appears critical for binding
NFAT (Figure 3B). To interfere sterically with the inter-
action, we expanded the dimensions of the Wing1 domain
of FOXP3. We inserted the additional sequence PDKPG
from Wing1 of HNF3 (FOXA3) between E401 and K402
of FOXP3 to generate the Insert mutant. (3) EARR mutant
(N361E H365A E399R E401R): To disrupt the NFAT:
FOXP3 interaction further, we made an N361E substitu-
tion designed to introduce a charge repulsion with E527
of NFAT1, as well as a H365A substitution expected to
remove favorable interactions between the imidazole
ring of H365 and the E’F loop of NFAT. These two muta-tions were combined with the Wing1 RR mutation to
generate the EARR mutant. (4) WRR (N361W E399R
E401R) and WWRR (T359W N361W E399R E401R)
mutants: A prominent feature of the NFAT1:FOXP2 inter-
face is the nearly perfect shape complementarity. In an
attempt to find a combination of mutations that would
completely abrogate the NFAT: FOXP3 interaction, we
introduced tryptophan residues in place of N361 and
T359 of FOXP3, in the hope that the bulky sidechains
would interfere with the interaction by clashing sterically
with E527 and I535 of NFAT1, respectively (Figures 3C
and 3D). The mutations were introduced in the context
of both the RR and Insert mutants with comparable re-
sults; only the data for the WRR and WWRR mutants are
shown here.
To confirm that the interface mutations did not affect
the DNA binding ability of FOXP3, we performed EMSA
assays with bacterially expressed wild-type and mutant
forkhead domains. The RR, Insert, EARR, and WRRCell 126, 375–387, July 28, 2006 ª2006 Elsevier Inc. 379
Figure 4. FOXP3:NFAT Interface Mutants Repress IL-2 Less Efficiently than Wild-Type FOXP3
(A) T cells from DO11+/ Ca/ mice were infected with wild-type and mutant FOXP3-IRES-GFP retroviruses. Three days later, cells were restimulated
for 6 hr with anti-CD3 and anti-CD28 and IL-2 expression was evaluated by intracellular cytokine staining.
(B) The same T cells were stained for intracellular FOXP3 without restimulation.
(C) Mean fluorescence intensities (MFI) of intracellular (i.c.) IL-2 and GFP (left) or intracellular FOXP3 and GFP (right) were determined for each incre-
ment of log GFP expression (see Experimental Procedures).mutants were comparable to wild-type FOXP3 in their abil-
ity to bind a consensus forkhead DNA element (V1P) (Li and
Tucker, 1993), although, as expected, they were impaired
in their ability to form a cooperative NFAT:FOXP3:DNA
complex (Figure S4). Because the forkhead domain of the
WWRR mutant formed inclusion bodies when expressed in
E. coli, precluding its biochemical characterization, we
evaluated the transcriptional competence of this mutant
by microarray analysis. A subset of genes was similarly
affected (upregulated or downregulated) in retrovirally
transduced CD4 T cells expressing either the wild-type
or the WWRR mutant FOXP3, whereas others were dif-
ferentially affected (expression altered by wild-type but
not by WWRR mutant FOXP3; V.H. and M.F., unpublished
data). Thus while the WWRR mutant is impaired in terms
of driving expression of certain genes, presumably those
dependent on cooperation with NFAT, it is nonetheless ac-
tive in driving transcription of other genes, presumably
those independent of NFAT:FOXP3 cooperation.
Mutation of NFAT-Interacting Residues Interferes
with Modulation of Gene Expression by FOXP3
We compared the activities of wild-type and mutant
FOXP3 proteins by retrovirally expressing them in primary380 Cell 126, 375–387, July 28, 2006 ª2006 Elsevier Inc.mouse CD4 T cells. All the interface mutations tested
decreased the ability of FOXP3 to inhibit IL-2 expression,
as judged by intracellular staining for IL-2 expression after
restimulation (Figures 4 and S5). The data are represented
both as cytofluorimetric contour plots and as plots of mean
fluorescence intensity (MFI) of IL-2 against GFP. In multi-
ple dose-response experiments, the Insert, RR, and
EARR mutant proteins showed a 2- to 4-fold shift in their
inhibitory capacity, while the tryptophan mutants were
even more impaired: the WRR mutation markedly reduced
and the WWRR mutation eliminated the ability of FOXP3 to
inhibit IL-2 (Figures 4A, 4C, and S5). The impairment was
not due to differences in expression levels or subcellular
localization: the wild-type and mutant FOXP3 proteins
showed equivalent expression and nuclear localization in
both NIH 3T3 cells and T cells after retroviral transduction
(Figures 4B, 4C, and S6). Thus the ability of FOXP3 to in-
hibit IL-2 production depends crucially on the integrity of
the FOXP3-NFAT interface, suggesting that FOXP3 in-
hibits IL-2 production by forming a cooperative NFAT:
FOXP3:DNA complex which replaces the NFAT:AP-1:
DNA complex at composite NFAT:AP-1 sites. Indeed, two
sites in the Il2 promoter were particularly good matches
for a consensus NFAT:FOXP site predicted based on the
Figure 5. Mutations in the NFAT:FOXP3 Interface Disrupt the Ability of FOXP3 to Upregulate CTLA4 and CD25
(A) T cells from DO11 Ca/ mice were infected with wild-type and mutant FOXP3-IRES-GFP retroviruses. Four days later, cells were stained for
intracellular (i.c.) CTLA-4 and cell-surface CD25. Left, cytofluorimetric contour plot. Right, CTLA-4 and CD25 MFI were plotted against GFP MFI.
(B) T cells from DO11 Ca/ mice were infected with wild-type and mutant FOXP3-IRES-GFP retroviruses. Two and four days later, cells were stained
for cell-surface CD25 and intracellular CTLA-4, respectively. Left, cytofluorimetric contour plot. Right, CTLA-4 and CD25 MFI were plotted against
GFP MFI.crystal structure (Table S2). We cannot rule out, however,
that the mutations block interaction with a partner protein
other than NFAT.
Retroviral transduction of FOXP3 also leads to increased
expression of the Treg markers CTLA-4, CD25, GITR, and
CD103 (Hori et al., 2003). In particular, Ctla4 has the char-
acteristics of an NFAT-dependent gene: it is induced in
a CsA-sensitive manner by treatments that induce intracel-
lular Ca2+ mobilization, and its promoter contains a com-
posite NFAT:AP-1 element that is a good match for the
consensus NFAT:FOXP site predicted based on the crystal
structure (Table S2) (Finn et al., 1997; Rao et al., 1997). In-
deed, mutations in the NFAT:FOXP3 interface interfered
with the ability of retrovirally-transduced FOXP3 to upregu-
late CTLA-4; the greatest deleterious effect was again ob-
served with the WWRR mutant (Figures 5A and 5B). The
mutations had similar but less striking effects on CD25,
CD103, and GITR expression (Figures 5A, 5B, and S6).
These results suggested that the NFAT:FOXP3 complex
could function not only as a repressor of the Il2 gene but
also as a direct or indirect activator of the Ctla4 gene,
and to a lesser extent the Cd25, Cd103, and Gitr genes.Chromatin immunoprecipitation (ChIP) experiments
confirmed that NFAT1 and FOXP3 could each occupy the
Il2, Ctla4, and Cd25 promoters, both in T cells retrovirally
transduced with FOXP3 and in ‘‘natural’’ CD4+CD25+
T regulatory cells that had been expanded with IL-2
(Masteller et al., 2005) (Figure 6). T cells were infected
with control or FOXP3-containing IRES-GFP retroviruses,
maintained in culture for 4 days (at which point about half
of each cell population expressed GFP), then restimulated
with PMA and ionomycin. Not only was FOXP3 binding
detected at the promoter under these conditions (Fig-
ure 6A), but surprisingly, NFAT1 binding to the promoters
was considerably increased in FOXP3-expressing cells
relative to nonexpressing cells, suggesting stabilization
through cooperative binding or increased epitope acces-
sibility (Figure 6B). We also tested expanded Treg popula-
tions (about 50% positive for Foxp3 because of over-
growth by contaminating Foxp3-negative cells in the
cultures) (Figure 6C). Ionomycin stimulation resulted in
binding of NFAT1 as well as Foxp3 to the promoters of the
Il2, Ctla4, and Cd25 target genes; binding was substan-
tially diminished in CsA-pretreated cells, again consistentCell 126, 375–387, July 28, 2006 ª2006 Elsevier Inc. 381
Figure 6. ChIP Assay for Binding of FOXP3 andNFAT1 to the Il2,Ctla4, andCd25Promoters in FOXP3-Transduced TCells and IL-2-
Expanded Tregs
Graphs display the numbers of copies of genomic DNA detected in each immunoprecipitation relative to a standard dilution of input. Results are
representative of two independent experiments in each case. Shown are mean and standard deviations of triplicate samples for the I12 and Ctla4
promoters, and mean and range of duplicate samples for the Cd25 promoter.
(A) T cells were infected with IRES-GFP retroviruses, control or encoding myc-tagged FOXP3, then cultured for 4 days and restimulated for 30 min
with PMA and ionomycin. Control and FOXP3-transduced cultures contained 55% and 45% GFP+ cells respectively.
(B) Chromatin from the stimulation described in (A) was used to assess binding of endogenous NFAT1 to the Il2, Ctla4, and Cd25 promoters.
(C) CD4+ CD25+ regulatory T cells were isolated from C57BL/6 mice and expanded in IL-2 (see Experimental Procedures). Foxp3+ cells in the cultures
were slowly overgrown by Foxp3 cells: the percentage of Foxp3+ cells determined by intracellular staining was 71% at day 4 and 47% at day 6. On
day 6, chromatin was prepared after restimulation with ionomycin for 30 min in the presence or absence of CsA. Binding of endogenous NFAT1 and
Foxp3 to the Il2, Ctla4, and Cd25 promoters was determined by ChIP and real-time PCR.with cooperative interactions between NFAT and Foxp3
(Figure 6C).
Notably, a truncated FOXP3 protein lacking its N-termi-
nal region (DN FOXP3) was not capable of either downre-
gulating IL-2 or upregulating CTLA-4 and CD25, despite
being similar to wild-type FOXP3 in its expression levels
and complete localization to the nucleus (Figure 7). De-
pending on the target gene involved, the N-terninal region
presumably recruits coactivator or corepressor proteins
that determine transcriptional activity. This effect may in-
volve interaction with a different region of NFAT or may
be entirely independent of NFAT.382 Cell 126, 375–387, July 28, 2006 ª2006 Elsevier Inc.Mutation of the NFAT Contact Surface Impairs
the Suppressor Function of FOXP3-Expressing Cells
Like bona fide regulatory T cells, primary T cells trans-
duced with FOXP3 are capable of suppressing the activity
of effector T cells in several animal models of autoimmune
disease (Fontenot et al., 2003; Hori et al., 2003; Jaeckel
et al., 2005). We asked whether this suppressive function
was compromised by handicapping the interaction of
FOXP3 with NFAT. We tested the FOXP3 interface mutants
in a mouse model of autoimmune diabetes (Katz et al.,
1995) in which regulatory T cells play a vital role. When
Th1 cells derived from BDC2.5/NOD TCR transgenic
Figure 7. The N-Terminal Region of FOXP3 Is Essential for FOXP3 Function
(A) Top, Diagram of FOXP3 indicating the zinc finger, the leucine zipper, and the forkhead (FKH) domain. The N-terminal deletion mutant is indicated.
Bottom left, equivalent levels of wild-type and N-terminal deletion mutant FOXP3 in lysates of retrovirally infected 3T3 cells as shown by Western
blotting. Actin serves as a loading control. Bottom right, nuclear localization of N-terminal deletion mutant in retrovirally infected 3T3 cells by immu-
nocytochemistry using anti-myc antibody.
(B) T cells from C57BL/6 mice were infected with IRES-GFP retroviruses encoding wild-type FOXP3 or the N-terminal deletion mutant of FOXP3. Four
days later, T cells were stained for intracellular CTLA-4 and CD25 without stimulation, and for IL-2 expression after stimulation with anti-CD3 and anti-
CD28 for 6 hr.T cells were transferred into neonatal NOD mice, essen-
tially all recipient animals developed diabetes within 7–
20 days (Katz et al., 1995); cotransfer of T cells expressing
wild-type FOXP3 protected the animals from disease fora period of at least six weeks (Figure 8). Cotransfer of cells
expressing the EARR and WRR mutants of FOXP3 pre-
vented the development of autoimmune disease initially,
but the protective effect broke down in 4/9 animals inFigure 8. T Regulatory Function Requires the NFAT:FOXP3 Interface
Th1 cells from BDC2.5/NOD mice were retrovirally transduced with control IRES-Thy1.1, wild-type, or mutant FOXP3-expressing viruses. Two days
after infection, Thy1.1-positive cells were sorted and transferred into neonatal NOD mice together with untransduced BDC2.5/NOD effector Th1 cells.
Recipient mice were monitored for 6 weeks for presentation of diabetes. The results are compiled from two independent experiments with at least four
mice per group in each case.Cell 126, 375–387, July 28, 2006 ª2006 Elsevier Inc. 383
the EARR group and 7/8 animals in the WRR group by day
20. Protection was also inadequate in mice receiving cells
expressing the insert mutant along with effector cells: 2/4
mice in this group developed rapid-onset diabetes, one
developed diabetes with a substantial delay, and one
was protected until termination of the experiment at day
41. Consistent with the strong effects of the WWRR muta-
tion in gene expression assays (Figures 4 and 5), the
WWRR mutant protein did not confer protection from dis-
ease: 9/10 mice that received cells expressing the WWRR
mutant showed rapid disease onset, thus resembling con-
trol groups that received effector cells only or effector cells
together with control Thy1.1-transduced T cells. Wild-type
and mutant FOXP3 proteins were expressed at equivalent
levels and localized to the nucleus (Figure S6).
We analyzed pancreata from mice in each group for in-
sulitis on day 6, before the clinical manifestation of diabe-
tes (Figure S7). At this time point, there was no apparent
difference in the degree of insulitis observed in mice
from the different groups. However, in mice coinjected
with effector cells and cells expressing wild-type FOXP3,
the early inflammation is converted to the innocuous con-
dition of ‘‘respectful’’ insulitis (Andre et al., 1996), thus pro-
tecting against diabetes. This conversion presumably
does not occur in mice that develop diabetes after being
given cells expressing FOXP3 interface mutants along with
effector cells. At day 20 after transfer, we also evaluated
the effector:suppressor T cell ratio in pancreatic lymph
nodes of surviving mice, by gating on CD4+ T cells and
analyzing the proportion of BDC2.5 TCR+ T cells that
were Thy1.1+ (i.e., had been transduced with FOXP3). Sur-
viving mice in all groups showed similar ratios of Thy1.1+
T cells relative to CD4+ BDC2.5+ effector T cells in the
draining lymph nodes (data not shown), showing that the
outbreak of disease is associated with loss of function of
the FOXP3-expressing cells, and not with their disappear-
ance. Thus the NFAT:FOXP3 complex controls Treg func-
tion but not the migration of FOXP3-expressing T cells to
pancreatic lymph nodes or their survival in vivo.
DISCUSSION
We have investigated the molecular interactions between
NFAT and FOXP3. We have shown that inhibition of NFAT
reporter activity by FOXP3 is apparent at NFAT:AP-1 com-
posite sites (Figure 1), and we have solved the crystal
structure of an NFAT:FOXP2:DNA complex (Figures 2
and 3). By introducing structure-guided mutations into
FOXP3, we have shown that graded disruption of the pre-
dicted NFAT:FOXP3 interface results in progressive loss
of function of FOXP3, both in gene expression assays
and in an in vivo model of autoimmune diabetes in mice
(Katz et al., 1995) (Figures 4, 5, and 8). By ChIP assays per-
formed in FOXP3-transduced T cells as well as in Foxp3-
expressing regulatory T cells expanded with IL-2, we have
confirmed concurrent binding of FOXP3 and NFAT1 to the
promoters of the Il2, Ctla4, and Cd25 target genes (Fig-
ure 6). We propose that a single transcription factor,384 Cell 126, 375–387, July 28, 2006 ª2006 Elsevier Inc.NFAT, directs two entirely contrary biological programs—
T cell activation and T cell tolerance—by recruiting unre-
lated transcriptional partners—AP-1 versus FOXP3—to
the regulatory regions of appropriate target genes
(Figure S8).
How do NFAT:FOXP3 complexes influence gene ex-
pression? FOXP3 and Fos-Jun occupy the same region
on the ARRE2 site of the Il2 promoter and their binding
is expected to be mutually exclusive (Figures 3 and S2).
Thus the simplest hypothesis is that FOXP3 competes
with AP-1 for cooperative binding with NFAT at a subset
of composite NFAT:AP-1 sites, among them the ARRE2
site and the 90 site in the Il2 promoter (Table S2). Never-
theless, simple competition for DNA binding sites is not
the entire explanation, as illustrated by the DN mutant
which has lost the ability to repress IL-2 expression, upre-
gulate CTLA-4 and CD25, and protect against diabetes
(Figure 7; V.H. and M.F., unpublished data), even though
it contains the forkhead DNA binding domain and both
predicted dimerization domains (leucine zipper and zinc
finger), is expressed at equivalent levels, and is fully local-
ized to the nucleus. The N-terminal region of FOXP3 that is
missing in the DN mutant may be actively involved in re-
cruiting transcriptional corepressors and coactivators to
the Il2 and Ctla4 promoters, respectively, either indepen-
dently or through a separate interaction with NFAT in the
NFAT:FOXP3 complex.
A remaining question is whether NFAT:FOXP3 coopera-
tion is required for thymic Treg differentiation. CD4+CD25+
thymocytes and peripheral T cells from NFAT1/
NFAT4/ double-knockout mice display T regulatory ac-
tivity in coculture assays (Bopp et al., 2005); however,
these cells have elevated nuclear levels of the third family
member, NFAT2 (NFATc1) (Ranger et al., 1998); thus it is
not yet clear whether Tregs can develop and function in
the complete absence of NFAT. To resolve this issue, we
are currently introducing our NFAT interface mutations
into the endogenous Foxp3 locus. On the other hand,
antigen and MHC class II are clearly needed for Treg dif-
ferentiation in the thymus as well as for the appearance
of adaptive/induced Tregs in the periphery (Bluestone
and Abbas, 2003). By analogy with the differentiation pro-
gram of helper T cells (Ansel et al., 2003), we propose that
Treg differentiation is initiated by antigen stimulation via
NFAT, most likely by imposing a positive feedback loop
that converts low-level stochastic expression of Foxp3
into sustained upregulation. This process is likely to be as-
sociated with chromatin structural changes that alter the
transcriptional competence of Foxp3 target genes as well
as the Foxp3 gene itself; consistent with this hypothesis,
chromatin at the Il2 promoter is less accessible to MNase
digestion in regulatory T cells than in naı¨ve CD4 T cells (Su
et al., 2004). In addition, Treg function requires restimula-
tion through the TCR (Hori et al., 2003), consistent with a
requirement for formation of the cooperative NFAT:FOXP3
complex; this behavior is similar to that of differentiated
Th1 and Th2 cells, which produce their signature cyto-
kines only under conditions where NFAT is activated.
Indeed, ChIP analysis shows that Foxp3 binding to Il2,
Ctla4, and other target genes in Tregs is stabilized when
NFAT is activated (Figure 6 and M.B., unpublished data),
in the same manner that NFAT activation stabilizes
Gata3 and Tbet binding to their respective target genes
(Avni et al., 2002; Lee et al., 2004).
Our data indicate that the immune system employs
NFAT as a common regulator both in effector T cells where
it forms a transcriptional complex with AP-1 and in regula-
tory T cells where it complexes with FOXP3. This ensures
that activation of self-reactive T cells and activation of
regulatory T cells are equally dependent on the immuno-
genicity of self-antigens, and are therefore balanced.
The combinatorial interaction of NFAT with Fos-Jun and
FOXP involves both overlapping and distinct interaction
surfaces, and individual residues in the overlapping region
display distinct modes of interaction with the different
partners. In particular, NFAT1 residues R466 and I467 in
the CX loop, and T533 in the E’F loop, are critical for
Fos-Jun binding (Chen et al., 1998; Macian et al., 2000)
but play no apparent role in binding to FOXP2 (Figures 3C
and S3). Mutation of these three residues yields NFAT1-
RIT, an NFAT1 mutant that is unable to interact with
AP-1 (Macian et al., 2000). A constitutively active version of
this protein, CA-NFAT1-RIT, is a potent inducer of T cell
anergy (Macian et al., 2002) and is also highly effective
at cooperating with FOXP3 (V.H., unpublished data). Pro-
longed antigen stimulation, in the absence of costimula-
tion, leads not only to NFAT-induced anergy but also to
the appearance of ‘‘adaptive’’ or ‘‘induced’’ Tregs in the
periphery (Apostolou and von Boehmer, 2004; Bluestone
and Abbas, 2003; Knoechel et al., 2005; Kretschmer
et al., 2005). Thus an attractive strategy for inducing
immune tolerance would be to develop small molecule
inhibitors that block NFAT:AP-1 interaction without inter-
fering with the interaction of NFAT and FOXP3.
EXPERIMENTAL PROCEDURES
Crystallization of the NFAT1:FOXP2:DNA Ternary Complex
The forkhead domain of human FOXP2 (residues 502–584) and the Rel
homology region (RHR) of human NFAT1 (residues 392–678) were
prepared as previously described (Chen et al., 1998; Stroud et al.,
2006) and mixed at a 1:1 molar ratio with murine ARRE2 DNA
(50-GGAAAATTTGTTTCA-30) in 5 mM HEPES, pH 7.63, 2 mM dithio-
threitol (DTT), 0.5 mM EDTA, and 150 mM NaCl. Crystals (space group
P21) were grown by hanging drop at 18
C, stabilized in harvest/
cryoprotectant buffer, and flash frozen with liquid N2 for cryocrystal-
lography. Statistics are presented in Table S1. Coordinates and struc-
tures have been deposited in the RCSB protein database under
accession code 2AS5.
Reporter Assays
Jurkat cells (10 3 106) were transfected by electroporation with HA-
tagged NFAT1 and/or myc-tagged human FOXP3 expression plas-
mids and luciferase reporter plasmids. Twenty-four hours later, cells
were stimulated for 6 hr with 1 mM ionomycin ± 10 nM PMA in the pres-
ence of 2 mM CaCl2 and luciferase activity was measured. When
CA-NFAT1 was used, endogenous NFAT activity was inhibited 24 hr
after transfection by pretreating cells with 1 mM cyclosporin A for
30 min before addition of stimuli. Results are plotted as relative lucifer-ase units after normalization to renilla, except in the case of Figure S1C
where luciferase values are normalized to the values obtained in trans-
fections with reporter plasmid alone. In Figures 1A and 1B, values are
normalized to the activity observed with CA-NFAT1 in the absence of
FOXP3. All results are representative of 2–3 independent experiments.
Electrophoretic Mobility Shift Assays (EMSAs)
Binding reactions were performed at room temperature using His6-
tagged wild-type NFAT1-DBD (Macian et al., 2000), His6-tagged
human FOXP3 forkhead domain (residues 335–419; described in Sup-
plemental Experimental Procedures), and NFAT:AP-1 ARRE2 probe
(50-CAAAGAGGAAAATTTGTTTCATACAGAAGG-30) (Jain et al., 1993)
in 10 ml of 10 mM Hepes, 5 mM DTT, 100 mM NaCl, 0.2 mM EDTA,
and 5% glycerol. DNA-protein complexes were resolved on 6% poly-
acrylamide gels.
Primary T Cell Cultures and Retroviral Transductions
CD4+ T cells were isolated by positive selection from mouse spleens
and lymph nodes, stimulated with anti-CD3 and anti-CD28 for 48 hr
(Ansel et al., 2004), and spin-infected with retrovirus containing super-
natant from Phoenix packaging cells transfected with retroviral ex-
pression plasmids (KMV IRES-GFP or MSCV IRES-Thy1.1, empty or
encoding wild-type or mutant myc-tagged FOXP3). CD4+CD25+ regu-
latory T cells were isolated from spleen and lymph nodes of C57Bl/6
mice by positive selection with anti-CD4 magnetic beads (Dynal) fol-
lowed by two rounds of CD25 positive selection (Miltenyi Biotec). T
cells were stimulated for 48 hr with anti-CD3, anti-CD28, and 2000
U/ml of IL-2, then cultured with 2000 U/ml IL-2 (Masteller et al., 2005).
Flow Cytometry and Intracellular Staining
T cells were stained intracellularly for CTLA-4 and FOXP3 on days 3 or
4 after retroviral infection, and for cell surface CD25 and GITR on days
2 and 5 after infection, respectively. Staining for IL-2 expression was
performed on day 3 after infection after restimulation for 6 hr with
anti-CD3 and anti-CD28; Brefeldin A (10 mg/ml; Sigma) was added
during the last 2–3 hr of stimulation. Flow cytometry data are presented
both as contour plots and as plots of mean fluorescence intensity (MFI)
of IL-2, CTLA-4, and CD25, normalized to that of the GFP-negative
population within each sample, against the mean fluorescence inten-
sity of GFP. FOXP3 expression was also evaluated by Western blotting
and immunocytochemistry using an IgG-purified rabbit antibody to
mouse Foxp3 (Cell-tech Chiroscience).
Chromatin Immunoprecipitation
Control and FOXP3-transduced T cells were stimulated with PMA (5
nM) and ionomycin (0.5 mM) for 30 min and chromatin immunoprecip-
itation was performed as previously described (Ansel et al., 2004) using
the following antibodies: anti-67.1 (against a peptide near the N termi-
nus of NFAT1), anti-T2B1 (against a peptide at the C terminus of
NFAT1 isoform C), anti-FOXP3 (Cell-tech Chiroscience), anti-myc
(9E10), or control rabbit preimmune serum. Binding of FOXP3 and
NFAT1 to Il2, Ctla4, and Cd25 promoters was determined by real-
time PCR. Results show the average and standard deviation of tripli-
cates, with the exception of the CD25 promoter in Figures 6A and
6B, which shows the average of duplicates. Expanded CD4+CD25+
T regulatory cells were stimulated for 30 min with ionomycin (1 mM)
with or without a 30 min preincubation with CsA (2 mM). Sequences
of primer pairs are given in Supplemental Experimental Procedures.
Induction of Diabetes in NOD Mouse Model
CD4+ T cells were isolated from BDC2.5/NOD mice, activated under
Th1 conditions (Ansel et al., 2004), and infected as described above
with MSCV IRES-Thy1.1 retrovirus, empty or encoding wild-type or
mutant FOXP3. Two days after infection, Thy1.1+ cells were sorted and
transferred into neonatal NOD mice at a 1:2 ratio (0.5 3 105: 1 3 105)
with untransduced BDC2.5/NOD Th1 cells (‘‘effector’’ cells). Recipient
mice were monitored for diabetes (urinary glucose more than 300 mg/dlCell 126, 375–387, July 28, 2006 ª2006 Elsevier Inc. 385
in two consecutive measurements) for 6 weeks. For histological scor-
ing of insulitis, paraffin sections of formalin-fixed pancreata were ex-
amined after hematoxylin-eosin staining.
Supplemental Data
Supplemental Data include two tables, eight figures, Experimental
Procedures, and References and can be found with this article online
at http://www.cell.com/cgi/content/full/126/2/375/DC1/.
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